187597-18-8

Usage

Uses

Used in Pharmaceutical Industry:
1-(6-METHYL[1,3]THIAZOLO[3,2-B][1,2,4]TRIAZOL-5-YL)-1-ETHANONE is used as a key intermediate in the synthesis of novel orally active mGluR5 antagonists, such as GSK2210875. 1-(6-METHYL[1,3]THIAZOLO[3,2-B][1,2,4]TRIAZOL-5-YL)-1-ETHANONE plays a crucial role in the development of new drugs targeting the metabotropic glutamate receptor 5 (mGluR5), which is implicated in various neurological and psychiatric disorders.
1-(6-METHYL[1,3]THIAZOLO[3,2-B][1,2,4]TRIAZOL-5-YL)-1-ETHANONE's ability to modulate mGluR5 activity makes it a valuable tool in the discovery and optimization of potential therapeutic agents for the treatment of conditions like Fragile X syndrome, schizophrenia, and anxiety disorders. By serving as a building block in the synthesis of mGluR5 antagonists, 1-(6-METHYL[1,3]THIAZOLO[3,2-B][1,2,4]TRIAZOL-5-YL)-1-ETHANONE contributes to the advancement of pharmaceutical research and drug development.

Upstream product

• 3179-31-5 2,3-dihydro-1H-1,2,4-triazole-3-thione 
• 1694-29-7 3-chloropentane-2,4-dione 
• 3179-31-5 2,4-dihydro-[1,2,4]triazole-3-thione 

Downstream Products

• 871122-21-3 1-(6-methylthiazolo[3,2-b][1,2,4]triazol-5-yl)-ethan-1-one oxime 
• 871122-21-3 1-(6-methylthiazolo[3,2-b][1,2,4]triazol-5-yl)-ethan-1-one oxime 
• 871122-21-3 1-(6-methylthiazolo[3,2-b][1,2,4]triazol-5-yl)-ethan-1-one oxime 

Relevant academic research and scientific papers

Synthesis of New Thiazolo[3,2-b][1,2,4]triazole Derivatives and Preliminary Evaluation of Their Biological Activity

Heterocyclization of 3-[(1H-1,2,4-triazol-3-yl)thio]pentane-2,4-dione afforded 1-(6-methylthiazolo[3,2-b][1,2,4]-triazol-5-yl)ethan-1-one, the reactions of which with hydroxylamine, hydrazincarboxamide, hydrazincarbothioamide, hydrazine hydrate and para-t

The identification of novel orally active mGluR5 antagonist GSK2210875

The identification of novel orally active mGluR5 antagonist GSK2210875 is described.

USE OF THIAZOLOIMIDAZOLES, THIAZOLOTETRAZOLES AND THIAZOLOTRIAZOLES AS MGLUR5 ANTAGONISTS

The invention relates to the use of thiazolotriazole, thiazoloimidazole and thiazolotetrazole derivatives of formula (I) in treating diseases and conditions for which antagonism of the mGluR5 receptor is beneficial, in particular substance related disorders. The invention also relates to certain novel derivatives. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.